Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors

Ravi Salgia
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois

Keywords
Angiogenesis inhibitors, fibroblast growth factors, non-small cell lung cancer, squamous cell carcinoma

Correspondence
Ravi Salgia, Professor of Medicine, Pathology, and Dermatology, Section of Hematology/Oncology, Department of Medicine, University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, Illinois 60637. Tel: (773) 702-6149; Fax: (773) 702-3002; E-mail: rsalgia@medicine.bsd.uchicago.edu

Funding Information
This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI).

Received: 17 December 2013; Revised: 6 February 2014; Accepted: 26 February 2014

Cancer Medicine 2014; 3(3):681–692
doi: 10.1002/cam4.238

Abstract
With the introduction of targeted agents primarily applicable to non-small cell lung cancer (NSCLC) of adenocarcinoma histology, there is a heightened unmet need in the squamous cell carcinoma population. Targeting the angiogenic fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling pathway is among the strategies being explored in squamous NSCLC; these efforts are supported by growth-promoting effects of FGF signaling in preclinical studies (including interactions with other pathways) and observations suggesting that FGF/FGFR-related aberrations may be more common in squamous versus adenocarcinoma and other histologies. A number of different anti-FGF/FGFR approaches have shown promise in preclinical studies. Clinical trials of two multitargeted tyrosine kinase inhibitors are restricting enrollment to patients with squamous NSCLC: a phase I/II trial of nintedanib added to first-line gemcitabine/cisplatin and a phase II trial of ponatinib for previously treated advanced disease, with the latter requiring not only squamous disease but also a confirmed FGFR kinase amplification or mutation. There are several ongoing clinical trials of multitargeted agents in general NSCLC populations, including but not limited to patients with squamous disease. Other FGF/FGFR-targeted agents are in earlier clinical development. While results are awaited from these clinical investigations in squamous NSCLC and other disease settings, additional research is needed to elucidate the role of FGF/FGFR signaling in the biology of NSCLC of different histologies.

Introduction
Histologic determination in advanced non-small cell lung cancer (NSCLC) has only recently become a fundamental consideration in guiding treatment decisions [1]. The most common histologic subtypes of NSCLC, which accounts for an estimated 85% of lung cancers, are adenocarcinoma (~30–50% of cases), squamous cell carcinoma (~30% of cases), and large cell carcinomas (~10% of cases) [2]. Historically, squamous cell carcinomas had been the predominant subtype but were supplanted by adenocarcinomas, likely reflecting changes related to the composition of cigarettes [2].

NSCLC-directed targeted therapies introduced into clinical practice over the past decade are mainly applicable to the treatment of patients with adenocarcinomas. These include the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib (Iressa®, AstraZeneca; Wilmington, DE) [3] and erlotinib (Tarceva®, Genentech; South San Francisco, CA) [4] and the anaplastic lymphoma kinase (ALK) inhibitor crizotinib (Xalkori®, Pfizer; New London, CT) [5]. Underlying aberrations conferring response to these agents (i.e., EGFR mutations and ALK gene rearrangements, the presence of which are to be confirmed by molecular analysis) are predominantly seen in adenocarcinomas [1, 6].
Additionally, the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (Avastin®, Genentech; South San Francisco, CA) [7] is approved specifically for nonsquamous NSCLC because of heightened bleeding-related safety issues among patients with squamous tumors [8, 9], an observation that has extended to some small molecule inhibitors, including sorafenib (Nexavar®, Bayer; Leverkusen, Germany) [10], sunitinib (SU11248, Sutent®, Pfizer; New London, CT) [11], and motesanib (Amgen; Thousand Oaks, CA) [12].

With the lack of applicability of the newest agents for treating NSCLC, squamous NSCLC poses unique challenges in the clinic and is being recognized as a subset with particularly high need for new therapies. Among tumors classified as squamous NSCLC, heterogeneity in angiogenic and proliferative behavior has been described [13]. To date, identifying serum tumor markers and growth factors with prognostic relevance specifically in squamous NSCLC has proved to be an elusive goal [14]. However, there is accumulating evidence that points toward a role for inhibiting the angiogenic fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling pathway in squamous NSCLC [15–17]. Following an overview of the FGF/FGFR signaling pathway, this article discusses key observations regarding its role in the development and progression of NSCLC and opportunities for its therapeutic inhibition in NSCLC, particularly for squamous cell disease.

**Overview of FGF and FGFRs**

**Biology and hallmarks**

FGFs belong to a family of highly conserved polypeptide growth factors [18, 19]. Most of the FGFs have a similar internal core structure, consisting of six identical amino acid residues and 28 highly conserved residues, with 10 of the latter interacting with the FGFRs [19]. Each of the four FGF tyrosine kinase receptors (FGFR1, FGFR2, FGFR3, and FGFR4) contains an extracellular component of three immunoglobulin-like domains (Ig-like I–III), a transmembrane domain, and an intracellular tyrosine kinase domain responsible for signal transmission to the cellular interior [18, 19]. Alternative splicing in Ig-like III of FGFR1 through three results in isoforms with varying degrees of binding specificity; FGFR IIIb and IIIc isoforms are mainly epithelial and mesenchymal, respectively [18, 19]. When FGFs bind to the FGFRs, dimerization results from a complex of two FGFs, two FGFRs, and two heparin sulfate chains (Fig. 1) and ultimately leads to FGFR activation, with the adaptor protein FGFR substrate two serving to recruit the Ras/mitogen-activated protein kinase (MAPK) and phosphoinositide-3 kinase (PI3K)/protein kinase B (Akt) pathways [18].

**Genetics of FGFRs**

A total of 22 FGF genes have been identified in humans, of which the chromosomal locations have been established with one exception (FGF16) [19]. Clustering within the genome (e.g., FGF3, FGF4, and FGF19, all on chromosome 11q13, and both FGF6 and FGF23 on chromosome 12p13) illustrates formation of the FGF family via gene and chromosomal duplication and translocation [19]. FGFR mutations have been associated with developmental disorders and identified across a number of malignancies, including lung cancer (Table 1) [18]. In addition to somatic FGFR1 and FGFR2 mutations (Table 1), FGFR4 mutations have been observed in lung adenocarcinoma with a potential contributing role to carcinogenesis [20, 21]. In a Japanese study of FGFR4 mutations and polymorphisms in surgically resected NSCLC, there were no FGFR4 mutations in the analyzed samples per direct sequencing [22]. However, when applying a genotyping assay, homozygous or heterozygous FGFR4 Arg388 allele was present in 61.8% of patients.

**Biologic effects of FGF signaling in normal physiology**

FGF/FGFR signaling plays a role in stimulating cell proliferation and migration and promoting survival of various types of cells [18]. Overall, FGFs are key contributors to not only angiogenesis but also organogenesis, including the formation of the heart, lungs, limbs, nervous system, and mammary and prostate glands [18].

**Role of the FGF Signaling Pathway in NSCLC**

Serum basic FGF (bFGF) levels have been shown to be increased in the NSCLC population (including both squamous cell and adenocarcinoma histologies) relative to healthy controls [23, 24]. In the past decade, research to elucidate the role of the FGF signaling pathway in NSCLC proliferation and differentiation has intensified. In one preclinical study performed with this research question in mind, Kuhn and colleagues found that intracellular levels and mRNA expression of bFGF correlated with the proliferation rate of all three NSCLC cell lines evaluated and that intracellular bFGF appears to function as an intrinsic growth factor in the setting of NSCLC [25].

There is a substantial and growing body of literature to support that the FGF signaling pathway interacts with
and influences other signaling pathways involved in the development and progression of NSCLC. For example, the VEGF and FGF/FGFR pathways have been shown to act synergistically in promoting tumor angiogenesis [26], while an upregulation of bFGF was recently proposed as one of the mechanisms by which the janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway mediates tumor angiogenesis in NSCLC [27].

One in vitro series involving a newly developed squamous NSCLC line (SCC-35), in which there was a highly significant correlation between the overexpression of FGF3 and EGFR, supports that co-overexpression of both growth factors may be implicated in the pathogenesis of lung carcinoma [28]. Furthermore, cancer-associated fibroblasts and the FGF/FGFR signaling pathway have been implicated in the development of intrinsic and acquired resistance to EGFR TKIs in patients with NSCLC [29–32].

Interestingly, there appear to be some FGF/FGFR signaling pathway-related distinctions between NSCLC cases of squamous cell versus adenocarcinoma histology [15–17, 33, 34]. Recently, researchers from the Dana–Farber Cancer Institute (DFCI) and the Broad Institute described a high prevalence of FGFR1 amplification specifically in squamous NSCLC, with amplification of a
Table 1. FGFR aberrations identified in human cancer.1

| Cancer          | Receptor | Aberration | Estimated prevalence | Association with other syndromes | Molecular consequence |
|-----------------|----------|------------|----------------------|----------------------------------|-----------------------|
| Breast          | FGFR1    | 8p11-12 amp| ~10% [18]            | Not known                        | Amplification of FGFR1|
| Bladder         | FGFR3    | R248C      | 5–20% [71–80]        | TDI                              | Enhanced kinase activity|
|                 | FGFR3    | S249C      | 25–69% [71–82]       | TDI                              | Enhanced kinase activity|
|                 | FGFR3    | G370/372C  | 2–9% [71–81]         | TDI                              | Enhanced kinase activity|
|                 | FGFR3    | S371/373C  | 1–4% [71–73, 76, 79, 80] | TDI                              | Enhanced kinase activity|
|                 | FGFR3    | Y373/375C  | 9–30% [71–81]        | TDI                              | Enhanced kinase activity|
|                 | FGFR3    | G380/382R  | <1–4% [71–73, 80, 82] | ACH                              | Enhanced kinase activity|
|                 | FGFR3    | A391/393E  | <1–1% [71, 73, 75, 81, 82] | CS                              | Enhanced kinase activity|
|                 | FGFR3    | K650/652E/Q/M/T | <1–6% (E), <1–2% (Q), 1–3% (M), 1–3% (M), 1–3% (M), 1–3% (M) | TDI, TDI, HCH, SADDAN, AN | Enhanced kinase activity|
| Prostate        | FGFR3    | S249C      | <1–6% [83, 84]       | TDI                              | Enhanced kinase activity|
|                 | FGFR3    | A391E      | <1–2% [83, 84]       | CS                              | Enhanced kinase activity|
| Endometrial     | FGFR2    | S252W      | 4–6% [85–87]         | AS                              | Altered ligand specificity|
|                 | FGFR2    | P253R      | 3% [85]              | AS                              | Altered ligand specificity|
|                 | FGFR2    | N549K      | 3–4% [86, 87]        | Not known                       | Enhanced kinase activity|
|                 | FGFR2    | K659N      | 1% [85–87]           | CR                              | Enhanced kinase activity|
| Lung            | FGFR1    | 8p12 amp   | 11–20% (SSC) [35, 88, 89] | Not known                        | Amplification of FGFR1|
|                 | FGFR2    | W290C      | 2–3% [85, 90, 91]    | PS                              | Not known²|
| Rhabdomyosarcoma| FGFR4    | N535K      | 3% [92]              | Not known                       | Enhanced kinase activity|
|                 | FGFR4    | V550E      | 3% [92]              | Not known                       | Enhanced kinase activity|
| Multiple myeloma| FGFR3    | t(4:14) trans | 15–23% [93–96]    | Not known                       | Overexpression of FGFR3|
| Brain           | FGFR1    | N56K       | 5% [100]             | Not known                       | Enhanced kinase activity|
|                 | FGFR1    | K656E      | NA                   | Not known                       | Enhanced kinase activity|
| Head and neck   | FGFR3    | R248C      | 5% [101]             | TDI                             | Enhanced kinase activity|
|                 | FGFR3    | S249C      | 1% [102]             | TDI                             | Enhanced kinase activity|
|                 | FGFR3    | G697C      | NA                   | Not known                       | Enhanced kinase activity|
| Melanoma        | FGFR2    | i642V      | 1% [103]             | Not known                       | Reduced kinase activity|
| EMS             | FGFR1    | 8p11-12 trans | 100% [104]          | Not known                       | Constitutively active |

FGFR, fibroblast growth factor receptor; amp, amplification; TDI/II, thanatophoric dysplasia I/II; ACH, achondroplasia; CS, Crouzon syndrome; HCH, hypochondroplasia; SADDAN, severe achondroplasia with developmental delay and acanthosis nigricans; AN, acanthosis nigricans; AS, Apert syndrome; CR, craniosynostosis; SCC, squamous cell carcinoma; PS, Pfeiffer syndrome; trans, translocation; NA, not available; EMS, 8p11 myeloproliferative disorder. The table, except for the column “Estimated prevalence” was reproduced with permission from Wesche and colleagues 2011 [18], Biochem J, 437:199-213 © the Biochemical Society.

¹Includes only the aberrations identified in human tumor samples.

²FGFR2 W290G forms ligand-independent dimers.

region of chromosome segment 8p11-12 (which includes the FGFR1 gene) in 21% of squamous tumors versus 3% of adenocarcinomas (P < 0.001) [15]. Similarly, a previously published German study had identified frequent and focal FGFR1 amplification in squamous NSCLC but not other histologic subtypes of lung cancer [16], while Japanese researchers have since reported a significantly higher rate of increased FGFR1 copy number in surgically resected squamous versus nonsquamous NSCLC (41.5% vs. 14.3%; P = 0.0066) [17]. However, there have been some reports to the contrary; for example, a recent German study designed to further elucidate the relevance of FGFR1 in lung cancer found that the proportion of samples displaying ≥4 copies of the FGFR1 gene was numerically but not statistically higher for squamous versus adenocarcinoma histology (10.5% vs. 4.7%; P = 0.278) [35].

Accumulating evidence points to a role for FGF signaling in the disease invasion and metastasis characteristic of NSCLC [36, 37]. In a recent study focused on identifying angiogenesis-related microRNAs (miRs) altered in NSCLC, one miR (miR-155) was found to be significantly...
correlated with FGF2 in the overall cohort \( (r = 0.17; P = 0.002) \), but even more strongly in the subset with nodal disease \( (r = 0.34; P < 0.001) \) [36].

FGFs/FGFRs have been identified as potential predictive and prognostic markers in NSCLC. In a number of studies, pretreatment bFGF levels have been correlated with prognosis in the NSCLC population [38–43]. In addition, recent evidence supports FGFR1 amplification as an independent negative prognostic factor (while exhibiting a dose-dependent association with cigarette smoking) in patients with squamous NSCLC [44]. A series of studies by Brattström and colleagues yielded mixed findings, with elevated serum bFGF levels reported as a favorable prognostic factor in an early series [45], but as a negative prognostic factor in subsequent reports [38, 39]. One of the studies was based on samples from 58 patients with surgically resected NSCLC, in whom a number of variables (including bFGF, as well as tumor volume, platelet counts, and serum VEGF levels) were significant prognostic factors on univariate analysis, whereas significance was retained only for bFGF on multivariate analysis [38]. There was a significant correlation between bFGF and disease recurrence \( (r = 0.34; P = 0.01) \), with rates of 78% and 40% for patients with elevated and normal bFGF levels, respectively. Additionally, this study found a significant correlation between bFGF levels and VEGF levels \( (r = 0.44; P < 0.001) \) and that the combination of growth factors was a significant prognostic factor on univariate but not multivariate analysis, although conclusions were confounded by the presence of elevated levels of both bFGF and VEGF in only six patients. In a Japanese retrospective analysis of predictors of long-term survival among 71 patients with surgically resected NSCLC of adenocarcinoma or squamous histology, mean bFGF levels were significantly higher in cases of metastatic nodal involvement and high levels were most strongly correlated with poor prognosis in patients also exhibiting high VEGF levels \( (P < 0.0001) \) [42]. Per multivariate analysis, bFGF and VEGF levels were each independent prognostic factors regardless of histology. Adding complexity to the topic of FGF as a prognostic factor in NSCLC, the implications of increased FGF expression have been shown to differ based on its presence in tumor cells (negative prognostic marker) versus stroma (favorable prognostic marker) [46, 47], with stromal expression postulated to inhibit NSCLC progression [48]. From a predictive biomarker standpoint, data on the contribution of baseline FGF levels on response to treatment for NSCLC have been mixed, with some but not all studies supporting a potential role for FGF to predict for treatment outcomes in various settings (including but not limited to antiangiogenic regimens) [49–52].

### Therapeutic Inhibition of FGF/FGFR Signaling

#### Preclinical observations in NSCLC

A number of preclinical observations collectively suggest that FGF/FGFR signaling may be exploited as a therapeutic target in the NSCLC population. In the aforementioned DFCI study, in which 21% of squamous tumors exhibited FGFR1 amplification, cell growth inhibition of an NSCLC line with focal FGFR1 amplification was demonstrated via FGFR1-specific small hairpin ribonucleic acids (shRNAs) or small molecule inhibitors [15]. Earlier preclinical series had supported inhibitory activity against NSCLC for a number of different anti-FGF/FGFR therapies, including a bFGF-neutralizing monoclonal antibody, antisense oligonucleotides, or bFGF antisense cDNA-expressing vector in one study [25] and a dominant-negative FGFR1 IIIc-green fluorescent protein fusion protein or small molecule inhibitors in another study [53]. Additional preclinical data have described the antiangiogenic and antitumor activities of individual multitargeted small molecule inhibitors—specifically those for which the targets include FGF/FGFRs—against NSCLC; these include cediranib (Regorafenib [54], nintedanib (BIBF 1120, Boehringer Ingelheim; Ingelheim, Germany) [55], pazopanib (Votrient[56], GlaxoSmithKline; London, UK) [56], ponatinib (Iclusig[57], ARIAD Pharmaceuticals, Inc, Cambridge, MA) [57], and a number of other investigational agents [16, 58–61]. Of note, inhibiting bFGF has been shown to increase the secretion of VEGF in NSCLC lines, supporting a therapeutic role for bFGF inhibition as a component of a multitargeted approach that also includes VEGF inhibition [62].

#### Clinical trials of FGF-targeting agents in NSCLC

Ongoing clinical trials of FGFR-inhibiting multitargeted tyrosine kinases in advanced squamous NSCLC or advanced NSCLC in general, including but not limited to squamous histology, are summarized in Table 2. Two multitargeted agents are being evaluated in a squamous-exclusive NSCLC population: (1) nintedanib, an inhibitor of VEGFR1 through 3, FGFR1 through 4, platelet-derived growth factor receptor (PDGFR) \( \alpha \) and \( \beta \), fms-related tyrosine kinase 3 (FLT-3), and members of the src family tyrosine kinase 3 (FLT-3), and members of the src family oncoprotein 1, nonreceptor tyrosine kinase (ABL) inhibitor (approved in December 2012 for treating two types of leukemia) that has also been shown to inhibit the four FGFRs, fueling research to determine its therapeutic potential as an FGFR inhibitor [57]. In an ongoing
placebo-controlled phase I/II study, nintedanib is being added to gemcitabine/cisplatin as first-line treatment of advanced or recurrent NSCLC specifically of squamous histology (NCT01346540). An estimated 165 patients will be enrolled, with primary outcomes of adverse events and dose-limiting toxicities in phase I and progression-free survival in phase II. In a completed, open-label, phase I trial (N = 26, including three with squamous histology) of first-line nintedanib in combination with carboplatin/paclitaxel in advanced NSCLC, among seven patients with a confirmed partial response, two had squamous histology and one had mixed large cell/squamous histology [63]. The most commonly reported adverse events (occurring in ≥10% of patients) related to nintedanib were diarrhea (53.8%), fatigue (50.0%), and nausea (46.2%). For ponatinib, a phase II trial is underway in patients with advanced squamous NSCLC that had progressed after the most recent treatment regimen, also requiring that patients have confirmed FGFR kinase amplification or mutation per genotyping (NCT01761747). This trial has a target accrual of 40 patients and a primary endpoint of response. Orantinib (formerly TSU-68 and SU6688; Taiho Pharmaceutical Co. Ltd, Tokyo, Japan), an oral TKI that targets VEGFR2, PDGFRβ, and FGFR1, was evaluated in a phase I trial (N = 37, including five patients with squamous NSCLC) in combination with carboplatin/paclitaxel as first-line therapy for advanced NSCLC, with 13 partial responses observed among 33 evaluable patients [64]. It was not specified as to whether any of these responses were in the squamous participants, and there are no known active clinical trials of this agent in advanced NSCLC as of this writing.

As shown in Table 2, two phase III trials have been initiated in NSCLC populations without exclusion of squamous cell histology, one of nintedanib plus docetaxel as second-line therapy in advanced or recurrent NSCLC (LUME-Lung 1 [NCT00805194]) and the other of cediranib in combination with first-line paclitaxel/carboplatin for advanced NSCLC (CAN-NCIC-BR29 [NCT00795340]). Results of LUME-Lung 1 show improvement in the primary outcome of progression-free survival with nintedanib/docetaxel versus placebo/docetaxel in the entire study population (median, 3.4 vs. 2.7 months; P = 0.0019) as well as in the histologic subsets with squamous disease (P = 0.02) or adenocarcinoma (P = 0.02) [65]. Significant improvement in overall survival (OS) was also observed in the nintedanib group among patients with adenocarcinoma histology (median, 12.6 vs. 10.3 months with placebo plus docetaxel; P = 0.0359). Cediranib primarily targets VEGFR2 but has demonstrated some inhibitory activity against FGF-induced proliferation, albeit 275-fold less selective than its inhibition of VEGF-induced proliferation [54]. A prior phase II trial (CAN-NCIC-BR24) found that cediranib (using a higher dose than in the phase III CAN-NCIC-BR29 trial above) plus paclitaxel/carboplatin was not tolerable. However, compared with other histologies, the squamous participants did not have an increased risk of severe pulmonary hemorrhage or adverse efficacy.

Table 2. Ongoing trials of multitargeted antiangiogenic tyrosine kinase inhibitors in squamous NSCLC.

| Agent | Phase | Regimen | Trial identifier |
|-------|-------|---------|-----------------|
| Cediranib (including squamous) | III | Cediranib + first-line paclitaxel/carboplatin for advanced or metastatic NSCLC | NCT00795340 |
| Nintedanib (BIBF 1120) | III | Nintedanib + second-line docetaxel for locally advanced and/or metastatic, or recurrent NSCLC | NCT00805194 |
| Pazopanib | III | Pazopanib as second-line therapy after progression on bevacizumab-containing-first-line therapy | NCT01262820 |
| | | Pazopanib + erlotinib as second- or third-line therapy for advanced NSCLC | NCT01027598 |
| | | Pazopanib + paclitaxel as first-line therapy for advanced NSCLC | NCT01179269 |
| | | Pazopanib + vinorelbine in metastatic NSCLC or breast cancer | NCT01060514 |
| Dovitinib | | Dovitinib after recent anti-VEGF therapy for advanced NSCLC or advanced colorectal cancer | NCT01676714 |
| Ponatinib | II/III | Ponatinib for progressive squamous NSCLC or head and neck cancers with FGFR kinase alterations | NCT01761747 |
| Nintedanib (BIBF 1120) | II | Nintedanib + first-line gemcitabine/cisplatin for advanced or recurrent squamous NSCLC | NCT01346540 |

NSCLC, non-small cell lung cancer; VEGF, vascular endothelial growth factor; FGFR, fibroblast growth factor receptor.

1Includes trials indexed on ClinicalTrials.gov with a status of recruiting, not yet recruiting, or active, not recruiting, as of September 2013.

2Phase I and II trials are included only for agents that have not reached phase III development for advanced NSCLC.

The most commonly reported adverse events (occurring in ≥10% of patients) related to nintedanib were diarrhea (53.8%), fatigue (50.0%), and nausea (46.2%). For ponatinib, a phase II trial is underway in patients with advanced squamous NSCLC that had progressed after the most recent treatment regimen, also requiring that patients have confirmed FGFR kinase amplification or mutation per genotyping (NCT01761747). This trial has a target accrual of 40 patients and a primary endpoint of response. Orantinib (formerly TSU-68 and SU6688; Taiho Pharmaceutical Co. Ltd, Tokyo, Japan), an oral TKI that targets VEGFR2, PDGFRβ, and FGFR1, was evaluated in a phase I trial (N = 37, including five patients with squamous NSCLC) in combination with carboplatin/paclitaxel as first-line therapy for advanced NSCLC, with 13 partial responses observed among 33 evaluable patients [64]. It was not specified as to whether any of these responses were in the squamous participants, and there are no known active clinical trials of this agent in advanced NSCLC as of this writing.

As shown in Table 2, two phase III trials have been initiated in NSCLC populations without exclusion of squamous cell histology, one of nintedanib plus docetaxel as second-line therapy in advanced or recurrent NSCLC (LUME-Lung 1 [NCT00805194]) and the other of cediranib in combination with first-line paclitaxel/carboplatin for advanced NSCLC (CAN-NCIC-BR29 [NCT00795340]). Results of LUME-Lung 1 show improvement in the primary outcome of progression-free survival with nintedanib/docetaxel versus placebo/docetaxel in the entire study population (median, 3.4 vs. 2.7 months; P = 0.0019) as well as in the histologic subsets with squamous disease (P = 0.02) or adenocarcinoma (P = 0.02) [65]. Significant improvement in overall survival (OS) was also observed in the nintedanib group among patients with adenocarcinoma histology (median, 12.6 vs. 10.3 months with placebo plus docetaxel; P = 0.0359). Cediranib primarily targets VEGFR2 but has demonstrated some inhibitory activity against FGF-induced proliferation, albeit 275-fold less selective than its inhibition of VEGF-induced proliferation [54]. A prior phase II trial (CAN-NCIC-BR24) found that cediranib (using a higher dose than in the phase III CAN-NCIC-BR29 trial above) plus paclitaxel/carboplatin was not tolerable. However, compared with other histologies, the squamous participants did not have an increased risk of severe pulmonary hemorrhage or adverse efficacy.
outcomes, which included the primary endpoint of progression-free survival [66]. Regarding new-onset cavitation, 10 of 40 cases among cediranib recipients and seven of 23 cases among placebo recipients were in patients with squamous tumors.

The EGFR-directed monoclonal antibody cetuximab (ERBITUX®, ImClone; New York, NY) [67] is another targeted therapy that is currently under clinical evaluation for squamous NSCLC. A phase II trial investigated first-line cetuximab in combination with platinum-based chemotherapy in advanced or recurrent NSCLC (eLung [NCT00828841]; squamous or nonsquamous disease), with OS as the primary endpoint. Presented results showed that median OS with cetuximab-containing chemotherapy was significantly longer in patients with nonsquamous versus squamous disease (9.9 vs. 8.7 months; \( P = 0.0082 \)) [68]. A phase III study is currently recruiting patients with advanced NSCLC of any histology (including squamous) to receive carboplatin/paclitaxel with or without bevacizumab and/or cetuximab (NCT00946712).

Finally, there are ongoing clinical investigations of other FGF/FGFR-targeted agents in advanced malignancies, although not specific to NSCLC or squamous NSCLC. The pan-FGFR inhibitors AZD4547 (AstraZeneca; Wilmington, DE; NCT01213160) and BGJ398 (Novartis; Cambridge, MA; NCT01004224; NCT01697605) are being evaluated in a phase I trial for advanced solid tumors; for BGJ398, eligibility criteria include confirmed FGFR-related alterations. A nonrandomized phase II trial of AZD4547 monotherapy is enrolling previously treated patients with FGFRI-amplified advanced squamous NSCLC (or FGFRI-amplified advanced breast cancer or FGFR2-amplified advanced esophagogastric cancer), with serial biopsies being performed to assess molecular effects (NCT01795768) [69]. Results are awaited from a phase I trial of the FGF ligand trap FP-1039 (FivePrime Therapeutics; South San Francisco, CA) in unresectable locally advanced or metastatic solid tumors (NCT00687505).

Future directions include studies to assess anti-FGF/FGFR agents in resectable disease (e.g., in combination with chemotherapy and/or radiation in the adjuvant setting), or even as a chemoprevention strategy [70]. Clinical trials to date have only investigated the efficacy of anti-FGF/FGFR agents in advanced NSCLC. Given the potential role of the FGF/FGFR signaling pathway in the pathogenesis of NSCLC, inhibition of this pathway in the adjuvant setting could provide benefit, especially for patients with squamous disease.

**Conclusions**

While there have been several molecularly targeted agents developed for the treatment of nonsquamous NSCLC, there appears to be a unique opportunity to develop anti-FGF/FGFR-based regimens for the treatment of NSCLC of squamous histology. Recent research findings supporting a propensity for squamous NSCLC to exhibit increased FGFRI gene amplification strengthen the rationale for this novel approach. Multitargeted small molecule inhibitors that inhibit FGFR along with other angiogenic pathways/receptors are the most advanced in clinical development, although none have yet to reach phase III evaluation in squamous-exclusive NSCLC study populations. Further research efforts are needed to more fully characterize the manner by and degree to which FGF signaling influences the underlying biology of specific NSCLC histologies.

**Acknowledgments**

This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI). Writing and editorial assistance was provided by Melissa Brunchchorst, PhD of MedErgy, which was contracted by BIPI for these services. The author meets criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE), is fully responsible for all content and editorial decisions, and was involved at all stages of manuscript development. The author received no compensation related to the development of this manuscript.

**Conflict of Interest**

None declared.

**References**

1. National Comprehensive Cancer Network. 2013. NCCN Clinical Practice Guidelines in Oncology™. Non-Small Cell Lung Cancer. V.2.2013. Available at http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf (accessed January 17, 2013).

2. Heighway, J., and D. C. Betticher. 2012. Lung: non-small cell lung carcinoma. Atlas Genet. Cytogenet. Oncol. Haematol. February 2004. Available at http://atlasgeneticsoncology.org/Tumors/LungNonSmallCellLungCancerV2.2012.html (accessed March 28, 2012).

3. Iressa. 2005. Iressa™ (gefitinib tablets) [package insert]. AstraZeneca Pharmaceuticals LP, Wilmington, DE.

4. Tarceva. 2013. Tarceva™ (erlotinib tablets) [package insert]. Genentech, Inc., South San Francisco, CA.

5. XALKORI. 2011. XALKORI™ (crizotinib) Capsules, oral [package insert]. Pfizer Labs, New York.

6. Yano, T., A. Haro, Y. Shikada, R. Maruyama, and Y. Maehara. 2011. Non-small cell lung cancer in never smokers as a representative ‘non-smoking-associated lung
cancer: epidemiology and clinical features. Int. J. Clin. Oncol. 16:287–293.
7. Avastin. 2012. AVASTIN® (bevacizumab) Solution for intravenous infusion [package insert]. Genentech, Inc., South San Francisco, CA.
8. Johnson, D. H., L. Fehrenbacher, W. F. Novotny, R. S. Herbst, J. J. Nemunaitis, D. M. Jabolons, et al. 2004. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22:2184–2191.
9. Sandler, A., R. Gray, M. C. Perry, J. Brahmer, J. H. Schiller, A. Dowlati, et al. 2006. Paclitaxel-carboplatin plus bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355:2542–2550.
10. Scagliotti, G., S. Novello, J. von Pawel, M. Reck, J. R. Pereira, M. Thomas et al. 2010. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J. Clin. Oncol. 28:1835–1842.
11. Socinski, M. A., S. Novello, J. R. Brahmer, R. Rosell, J. M. Sanchez, C. P. Belani, et al. 2008. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J. Clin. Oncol. 26:650–656.
12. Amgen. 2010. Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-squamous NSCLC Patients in the Motesanib MONET1 Trial. Available at http://www.amgen.com/media/media_pr_detail.jsp?year=2009&releaseID=1255738 (accessed May 12, 2010).
13. Mattern, J., R. Koomagi, and M. Volm. 1999. Biological characterization of subgroups of squamous cell lung carcinomas. Clin. Cancer Res. 5:1459–1463.
14. Nieder, C., N. Andratschke, B. Jeremic, and M. Molls. 2003. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Res. 23:5117–5123.
15. Dutt, A., A. H. Ramos, P. S. Hammerman, C. Mermel, J. Cho, T. Sharifinia, et al. 2011. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PloS One 6:e20351.
16. Weiss, J., M. L. Sos, D. Seidel, M. Peifer, T. Zander, J. M. Heuckmann, et al. 2010. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2:62ra93.
17. Sasaki, H., M. Shitara, K. Yokota, Y. Hikosaka, S. Moriyama, M. Yano, et al. 2012. Increased FGFR1 copy number in lung squamous cell carcinomas. Mol. Med. Rep. 5:725–728.
18. Wesche, J., K. Haglund, and E. M. Haugsten. 2011. Fibroblast growth factors and their receptors in cancer. Biochem. J. 437:199–213.
19. Ornitz, D. M., and N. Itoh. 2001. Fibroblast growth factors. Genome Biol. 2(REVIEW/S3005).
20. Ding, L., G. Getz, D. A. Wheeler, E. R. Mardis, M. D. McLellan, K. Cibulskis, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069–1075.
21. Marks, J. L., M. D. McLellan, M. F. Zakowski, A. E. Lash, Y. Kasai, S. Broderick, et al. 2007. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One 2:e426.
22. Sasaki, H., K. Okuda, O. Kawano, H. Yukie, M. Yano, and Y. Fujii. 2008. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer. Oncol. Rep. 20:1125–1130.
23. Dudek, A. Z., and H. Mahaseth. 2005. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest. 23:193–200.
24. Ůeno, K., Y. Inoue, T. Kawaguchi, S. Hosoe, and M. Kawahara. 2001. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 31:213–219.
25. Kuhn, H., C. Kopff, J. Konrad, A. Riedel, C. Gessner, and H. Wirtz. 2004. Influence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell lines. Lung Cancer 44:167–174.
26. Slodkowska, J., J. Sikora, K. Roszkowski-Sliz, A. Radomyski, and W. Androsiuk. 2000. Expression of vascular endothelial growth factor and basic fibroblast growth factor receptors in lung cancer. Anal. Quant. Cytol. Histol. 22:398–402.
27. Zhao, M., F. H. Gao, J. Y. Wang, F. Liu, H. H. Yuan, W. Y. Zhang, et al. 2011. JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer 73:366–374.
28. Tai, A. L., J. S. Sham, D. Xie, Y. Fang, Y. L. Wu, L. Hu, et al. 2006. Co-overexpression of fibroblast growth factor 3 and epidermal growth factor receptor is correlated with the development of nonsmall cell lung carcinoma. Cancer 106:146–155.
29. Ware, K. E., M. E. Marshall, L. R. Heasley, L. Marek, T. K. Hinz, P. Hercule, et al. 2010. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One 5:e14117.
30. Mink, S. R., S. Vashistha, W. Zhang, A. Hodge, D. B. Agus, and A. Jain. 2010. Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol. Cancer Res. 8:809–820.
31. Marek, L., K. E. Ware, A. Fritzsche, P. Hercule, W. R. Helton, J. E. Smith, et al. 2009. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol. Pharmacol. 75:196–207.

32. Kono, S. A., M. E. Marshall, K. E. Ware, and L. E. Heasley. 2009. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist. Updat. 12:95–102.

33. Beau-Faller, M., M. P. Gaub, A. Schneider, E. Guérin, N. Meyer, X. Ducrocq, et al. 2003. Allelic imbalance at loci containing FGFR, FGF, c-Met and HGF candidate genes in non-small cell lung cancer sub-types, implication for progression. Eur. J. Cancer 39:2538–2547.

34. Behrens, C., H. Y. Lin, J. J. Lee, M. G. Raso, W. K. Hong, I. Wistuba, et al. 2008. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin. Cancer Res. 14:6014–6022.

35. Kohler, L. H., M. Mireskandari, T. Knosel, A. Altendorf-Hofmann, A. Kunze, A. Schmidt, et al. 2012. FGFR1 expression and gene copy numbers in human lung cancer. Virchows Arch. 461:49–57.

36. Donnem, T., C. G. Fenton, K. Lonvik, T. Berg, K. Eklo, S. Muller-Tidow, C. Diederichs, E. Bulk, T. Pohle, I. I. Wistuba, et al. 2008. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. PLoS One 7:e29671.

37. Muller-Tidow, C., S. Diederichs, E. Bulk, T. Pohle, B. Steffen, J. Schwäble, et al. 2005. Identification of metastasis-associated receptor tyrosine kinases in non-small-cell lung cancer. Cancer Res. 65:1778–1782.

38. Brattstrom, D., M. Bergqvist, P. Hesselius, A. Larsson, K. Lamberg, J. Wernlund, et al. 2002. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 37:57–63.

39. Brattstrom, D., M. Bergqvist, P. Hesselius, A. Larsson, G. Wagenius, and O. Brodin. 2004. Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer 43:55–62.

40. Joensuu, H., A. Anttonen, M. Eriksson, R. Mäkitaro, H. Alifiéan, V. Kinnula, et al. 2002. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res. 62:5210–5217.

41. Shou, Y., T. Hirano, Y. Gong, Y. Kato, K. Yoshida, T. Ohira, et al. 2001. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br. J. Cancer 85:1706–1712.

42. Iwasaki, A., M. Kuwahara, Y. Yoshinaga, and T. Shirakusa. 2004. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur. J. Cardiothorac. Surg. 25:443–448.

43. Bremnes, R. M., C. Camps, and R. Sirera. 2006. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51:143–158.

44. Kim, H. R., D. J. Kim, D. R. Kang, J. G. Lee, S. M. Lim, C. Y. Lee, et al. 2013. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J. Clin. Oncol. 31:731–737.

45. Brattstrom, D., M. Bergqvist, A. Larsson, J. Holmertz, P. Hesselius, L. Rosenberg, et al. 1998. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res. 18:1123–1127.

46. Donnem, T., K. Al-Shibli, S. Al-Saad, L. T. Busund, and R. M. Bremnes. 2009. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J. Thorac. Oncol. 4:578–585.

47. Andersen, S., T. Donnem, S. Al-Saad, K. Al-Shibli, L. T. Busund, and R. M. Bremnes. 2009. Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiotherapy. J. Thorac. Oncol. 4:463–471.

48. Guido, F., G. Fontanini, C. Reina, A. M. Vignola, A. Angeletti, and G. Bonsignore. 1999. The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. Hum. Pathol. 30:788–794.

49. Young, R. J., A. W. Tin, N. J. Brown, M. Jitlal, S. M. Lee, and P. J. Woll. 2012. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. Br. J. Cancer 106:1153–1159.

50. Rades, D., C. Setter, O. Dahl, S. E. Schidl, and F. Noack. 2012. Fibroblast growth factor 2—a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 82:442–447.

51. Isa, S., T. Kawaguchi, S. Teramukai, K. Minato, Y. Ohsaki, K. Shibata, et al. 2009. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J. Thorac. Oncol. 4:1104–1110.

52. Dowlati, A., R. Gray, A. B. Sandler, J. H. Schiller, and D. H. Johnson. 2008. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor.
factor in patients with non-small cell lung cancer treated
with chemotherapy with or without bevacizumab—an
Eastern Cooperative Oncology Group Study. Clin. Cancer
Res. 14:1407–1412.
53. Fischer, H., N. Taylor, S. Allerstorfer, M. Grusch,
G. Sonvilla, K. Holzmann, et al. 2008. Fibroblast growth
factor receptor-mediated signals contribute to the
malignant phenotype of non-small cell lung cancer cells:
therapeutic implications and synergism with epidermal
growth factor receptor inhibition. Mol. Cancer Ther.
7:3408–3419.
54. Wedge, S. R., J. Kendrew, L. F. Hennequin, P. J.
Valentine, S. T. Barry, S. R. Brave, et al. 2005. AZD2171:
a highly potent, orally bioavailable, vascular endothelial
growth factor receptor-2 tyrosine kinase inhibitor for the
treatment of cancer. Cancer Res. 65:4389–4400.
55. Hilberg, F., G. J. Roth, M. Krasak, S. Kautschitsch,
W. Sommergruber, U. Tontsch-Grunt, et al. 2008. BIBF
1120: triple angiokinase inhibitor with sustained receptor
blockade and good antitumor efficacy. Cancer Res.
68:4774–4782.
56. Kumar, R., V. B. Knick, S. K. Rudolph, J. H. Johnson,
R. M. Crosby, M. C. Crouthamel, et al. 2007.
Pharmacokinetic-pharmacodynamic correlation from
mouse to human with pazopanib, a multitissue
angiogenesis inhibitor with potent antitumor and
antiangiogenic activity. Mol. Cancer Ther. 6:2012–2021.
57. Gorgit, J. M., M. J. Wong, L. Moran, S. Wardwell, Q. K.
Mohemmad, N. I. Narasimhan, et al. 2012. Ponatinib
(AP24534), a multitargeted pan-FGFR inhibitor with
activity in multiple FGFR-amplified or mutated cancer
models. Mol. Cancer Ther. 11:690–699.
58. Cao, Z. X., R. L. Zheng, H. J. Lin, S. D. Luo, Y. Zhou,
Y. Z. Xu, et al. 2011. SKLB610: a novel potential
inhibitor of vascular endothelial growth factor receptor
tyrosine kinases inhibits angiogenesis and tumor growth
in vivo. Cell Physiol. Biochem. 27:565–574.
59. Muruganandham, M., M. Lupu, J. P. Dyke, C. Matei,
M. Linn, K. Packman, et al. 2006. Preclinical evaluation
of tumor microvascular response to a novel
antiangiogenic/antitumor agent RO0281501 by dynamic
contrast-enhanced MRI at 1.5 T. Mol. Cancer Ther.
5:1950–1957.
60. Kolinsky, K., C. Tovar, Y. E. Zhang, A. Rallkar, H. Yang,
D. Carvajal, et al. 2011. Preclinical evaluation of the novel
multi-targeted agent R1530. Cancer Chemother.
Pharmacol. 68:1585–1594.
61. Zhang, J., L. Zhang, X. Su, M. Li, L. Xie, F. Malchers,
et al. 2012. Translating the therapeutic potential of
AZD4547 in FGFR1-amplified non-small cell lung cancer
through the use of patient-derived tumor xenograft
models. Clin. Cancer Res. 18:6658–6667.
62. Kuhn, H., J. Konrad, S. Holtz, A. Salameh, C. Gessner,
S. Hammerschmidt, et al. 2006. Enhanced expression of
VEGF following bFGF inhibition in non-small cell lung
cancer cell lines. Lung Cancer 54:149–153.
63. Doebele, R. C., P. Conkling, A. M. Traynor, G. A.
Otterson, Y. Zhao, S. Wind, et al. 2012. A phase I,
open-label dose-escalation study of continuous treatment
with BIBF 1120 in combination with paclitaxel and
carboplatin as first-line treatment in patients with advanced
non-small-cell lung cancer. Ann. Oncol. 23:2094–2102.
64. Okamoto, I., H. Yoshioka, K. Takeda, M. Satouchi,
N. Yamamoto, T. Seto, et al. 2012. Phase I clinical study
of the angiogenesis inhibitor TSU-68 combined with
carboplatin and paclitaxel in chemotherapy-naive patients
with advanced non-small cell lung cancer. J. Thorac.
Oncol. 7:427–433.
65. Reck, M., R. Kaiser, A. Mellemaarda, J. Y. Du uillard,
S. Orlov, M. J. Krzakowski, et al. 2013. Nintedanib (BIBF
1120) plus docetaxel in NSCLC patients progressing after
first-line chemotherapy: LUME Lung 1, a randomized,
double-blind phase III trial. J. Clin. Oncol. 31: Abstract
LBA8011.
66. Goss, G. D., A. Arnold, F. A. Shepherd, M. Dediu, T. E.
Ciuleanu, D. Fenton, et al. 2010. Randomized,
double-blind trial of carboplatin and paclitaxel with
either daily oral cediranib or placebo in advanced
non-small-cell lung cancer: NCIC Clinical Trials Group
BR24 study. J. Clin. Oncol. 28:49–55.
67. ERBITUX. 2012. ERBITUX® (cetuximab) injection, for
intravenous infusion [package insert]. ImClone LLC,
Branchburg, NJ.
68. Schwartzberg, L. S., K. Tauer, J. Atkins, K. Sivarajan,
V. Patel, B. Bastos, et al. 2012. ELUNG: A multicenter,
randomized phase IIIB trial of “standard” platinum
doublets plus cetuximab (CET) as first-line treatment of
recurrent or advanced non-small cell lung cancer
(NSCLC). Ann. Oncol. 23:ix22. Abstract LBA30.
69. Smyth, E. C., N. C. Turner, S. Popat, S. Morgan,
K. Owen, A. Gillbanks, et al. 2013. FGFR:
Proof-of-concept study of AZD4547 in patients with
FGFR1 or FGFR2 amplified tumours. J. Clin. Oncol.
31: Abstract TPS2626.
70. Johnson, K. A., and P. H. Brown. 2010. Drug
development for cancer chemoprevention: focus on
molecular targets. Semin. Oncol. 37:345–358.
71. Tomlinson, D. C., O. Baldo, P. Harnden, and M. A.
Knowles. 2007. FGFR3 protein expression and its
relationship to mutation status and prognostic variables
in bladder cancer. J. Pathol. 213:91–98.
72. Zieger, K., L. Dyrskjot, C. Wiuf, J. L. Jensen, C. L.
Branchburg, NJ.
study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J. Clin. Oncol. 24:3664–3671.

74. van Oers, J. M., I. Lurkin, A. J. van Exsel, Y. Nijssen, B. W. van Rhijn, M. N. van der Aa, et al. 2005. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin. Cancer Res. 11:7743–7748.

75. van Rhijn, B. W., A. N. Vis, T. H. van der Kwast, W. J. Kirkels, F. Radvanyi, E. C. Ooms, et al. 2003. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J. Clin. Oncol. 21:1912–1921.

76. Jебар, A. H., C. D. Hurst, D. C. Tomlinson, C. Johnston, C. F. Taylor, and M. A. Knowles. 2005. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24:5218–5225.

77. Bakkar, A. A., H. Wallerand, F. Radvanyi, J. B. Lahaye, S. Pissard, L. Lecerf, et al. 2003. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 63:8108–8112.

78. Billeroye, C., D. Chopin, M. H. Aubriot-Lorton, D. Ricol, S. G. de Medina, J. C. Serizawa, R. R., U. Ralfkiaer, K. Steven, G. W. Lam, Kompier, L. C., I. Lurkin, M. N. van der Aa, et al. 2005. FGFR3 mutations and hypermethylation events. Int. J. Cancer 129:78–87.

79. Kompier, L. C., I. Lurkin, M. N. van der Aa, B. W. van Rhijn, T. H. van der Kwast, and E. C. Zwarthoff. 2010. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5:e13821.

80. van Rhijn, B. W., A. A. van Tilborg, I. Lurkin, J. Bonaventure, A. de Vries, J. P. Thiery, et al. 2002. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur. J. Hum. Genet. 10:819–824.

81. Hernandez, S., S. de Muga, L. Agell, N. Juanpere, R. Esquena, J. A. Lorente, et al. 2009. FGFR3 mutations in prostate cancer: association with low-grade tumors. Mod. Pathol. 22:848–856.

82. Koufou, S., J. C. Lunz, A. Borchardt, B. Keck, B. Kneitz, N. T. Gaisa, et al. 2010. Mutational activation of FGFR3 is not involved in the development of prostate cancer. Pathobiology 77:249–252.

83. Dutt, A., H. B. Salvesen, T. H. Chen, A. H. Ramos, R. C. Onufrio, C. Hatton, et al. 2008. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. U S A 105:8713–8717.

84. Pollock, P. M., M. G. Gartside, L. C. Dejeza, M. A. Powell, M. A. Mallon, H. Davies, et al. 2007. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26:7158–7162.

85. Byron, S. A., M. G. Gartside, C. L. Wellsell, M. A. Mallon, J. B. Keenan, M. A. Powell, et al. 2008. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res. 68:6902–6907.

86. Craddock, K. J., O. Ludkovski, J. Sykes, F. A. Shepherd, and M. S. Tsao. 2013. Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma. J. Thorac. Oncol. 8:1371–1377.

87. Malchers, F., F. Dietlein, J. Schottle, X. Lu, K. Nogova, K. Albus, et al. 2014. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov. 4:246–257.

88. Davies, H., C. Hunter, R. Smith, P. Stephens, C. Greenman, G. Bignell, et al. 2005. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 65:7591–7595.

89. Liao, R. G., J. Jung, J. Tchaicha, M. D. Wilkerson, S. Schmiedel, J. Schottle, X. Lu, K. Nogova, K. Albus, et al. 2014. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov. 4:246–257.

90. Taylor, J. G., A. T. Cheuk, P. S. Tsang, J. Y. Chung, Y. K. Song, K. Desai, et al. 2009. FGFR3 mutations and hypermethylation events. Int. J. Cancer 129:78–87.

91. Intini, D., L. Baldini, S. Fabris, L. Lombardi, G. Ciceri, A. Maiolo, et al. 2001. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br. J. Haematol. 114:362–364.

92. Taylor, J. G., A. T. Cheuk, P. S. Tsang, J. Y. Chung, Y. K. Song, K. Desai, et al. 2009. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest. 119:3395–3407.

93. Vignarelli, G. Colombo, et al. 2000. Detection of t(4;14) translocation associated with IGH-MMSET fusion transcripts. Mod. Pathol. 13:871–877.

94. Knockaert, D., L. Lombardi, S. Fabris, L. Baldini, G. Ciceri, A. Maiolo, et al. 2001. Analysis of FGFR3 gene mutations in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res. 60:4058–4061.
96. Nemec, P., Z. Zemanova, P. Kuglik, K. Michalova, J. Tajtlova, P. Kaisarova, et al. 2012. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk. Lymphoma 53:920–927.

97. Soverini, S., C. Terragna, N. Testoni, D. Ruggeri, P. Tosi, E. Zamagni, et al. 2002. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. Haematologica 87:1036–1040.

98. Ronchetti, D., A. Greco, S. Compasso, G. Colombo, P. Dell’Era, T. Otsuki, et al. 2001. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 20:3553–3562.

99. Chesi, M., E. Nardini, L. A. Brents, E. Schröck, T. Ried, W. M. Kuehl, et al. 1997. Frequent translocation t(4;14) (p16.3q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 16:260–264.

100. Rand, V., J. Huang, T. Stockwell, S. Ferriera, O. Buzko, S. Levy, et al. 2005. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc. Natl. Acad. Sci. U S A 102:14344–14349.

101. Chou, A., N. Dekker, and R. C. Jordan. 2009. Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 107:535–541.

102. Shotelersuk, V., C. Ittiwut, K. Shotelersuk, S. Triratanachat, Y. Poovorawan, and A. Mutirangura. 2001. Fibroblast growth factor receptor 3 S249C mutation in virus associated squamous cell carcinomas. Oncol. Rep. 8:1301–1304.

103. Gartside, M. G., H. Chen, O. A. Ibrahim, S. A. Byron, A. V. Curtis, C. L. Wellens, et al. 2009. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol. Cancer Res. 7:41–54.

104. Jackson, C. C., L. J. Medeiros, and R. N. Miranda. 2010. 8p11 myeloproliferative syndrome: a review. Hum. Pathol. 41:461–476.